Personalised mRNA vaccine reduced melanoma recurrence risk in phase 3 trial
publishers 18articles 19first reported 23 Oct, 07:49 UTCdeveloping since 23 Oct · 9 editions
A personalised mRNA cancer vaccine given with pembrolizumab reduced the risk of recurrence or death among patients with high-risk melanoma by 42% compared with pembrolizumab alone, according to results from a large phase 3 trial.
The INTerpath-001 trial enrolled 1,137 patients with stage IIB to IV melanoma whose tumours had been surgically removed but who remained at high risk of the cancer returning. Participants had not previously received drug treatment for their cancer.
The vaccine, called intismeran, is individually produced using the unique genetic features of each patient’s tumour. It is designed to train the immune system to recognise and attack cancer cells. Unlike conventional vaccines that prevent disease, it is a therapeutic vaccine administered after a cancer diagnosis.
Researchers compared intismeran combined with the immunotherapy pembrolizumab against pembrolizumab alone. The findings are due to be presented by Professor Georgina Long of Melanoma Institute Australia and the University of Sydney at the European Society for Medical Oncology Congress 2026.
Long described the results as a new personalised approach to reducing the risk that melanoma will recur or lead to death. The BBC, New York Times, Washington Post and Yahoo also reported that the vaccine substantially lowered the likelihood of melanoma returning.
HOW THIS STORY WAS MADE
Written from 8 articles, 2 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 4 h after the record first saw the story; the editor kept it as written.
- Publishers
- 18
- Source articles
- 19
- Given to the writer
- 8, 2 with the article's own text
- Independent newsrooms
- 8
- This version written
- 4 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →